Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2013

View Archived Issues

Tumor dependency of an EGFR-targeted probody

Novel human type 5 adenovirus-based tuberculosis vaccine presented by Canadian group

Roche and Molecular Partners to develop new cancer treatments

Cerus submits final PMA module for INTERCEPT Blood System for plasma

Genmab and Janssen Biotech expand DuoBody platform collaboration

Phase I/II study of recombinant human beta-glucuronidase in MPS VII begins

OmniBiome Therapeutics to focus on preventing preterm labor

Flag Therapeutics and Duquesne University collaborate on targeted oncology compounds

ReGenX Biosciences and Lysogene enter into agreement for lysosomal storage disorder

Proteostasis Therapeutics collaborates with Biogen Idec for neurodegenerative diseases

DWTI announces the initiation of a preclinical study of H-1129 in Japan

Ono seeks clearance to begin phase I study of ONO-7268MX2

ImQuest BioSciences presents a novel anti-HIV microbicide gel

Novel CB2 agonists demonstrate efficacy in animal models of inflammatory pain

Sunovion presents the discovery of novel selective mGlu5 PAMs

Pharmacological data presented for a selective nAChR desensitizer

Researchers at Sanofi disclose new CXCR3 receptor antagonists

German group patents novel dermatological agents

Novartis presents novel anti-BAFF-R afucosylated human antibody

Bayer Schering Pharma presents novel MAPK inhibitors for cancer

Boehringer Ingelheim Pharma discloses novel sodium channel blockers

Roche and Genentech divulge new DLK inhibitors for neurodegenerative disorders

Scientists at Novartis design novel agents for cancer

Baxter seeks FDA approval for OBI-1 in acquired hemophilia A

Spectrum Pharmaceuticals submits NDA for belinostat

FDA grants fast track designation to Navidea Biopharmaceuticals' Lymphoseek

FDA grants QIDP and fast track designation to AeroVanc

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...